Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $16.44 million versus the consensus estimate of $15.85 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight